Related Experiment Video
Updated: Feb 2, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma
Qiang Zhao1, Baoan Hong2, Tiezhu Liu3
1Department of Urology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing 100142, P.R. China.
Abstract:
Vascular endothelial growth inhibitor (VEGI) has been identified as an anti‑angiogenic cytokine. However, the effects of VEGI174 protein, and its functional domain peptides V7 and V8, on renal cell carcinoma (RCC) remain unknown. In the present study, the protein and peptides were biosynthesised as experimental agents. The A498 and 786‑O RCC cell lines, and an established mouse xenograft model, were separately treated with VEGI174, V7 or V8. Cellular functions, including proliferation, migration and invasion, were subsequently detected. Cell migration and invasion were monitored using the xCELLigence system. Furthermore, tumour growth and mouse behaviours, including mobility, appetite and body weight, were assessed. The results demonstrated that VEGI174, V7 and V8 inhibited the proliferation, migration and invasion of A498 and 786‑O cell lines when administered at concentrations of 1 and 100 pM, 10 nM and 1 µM. The inhibitory effects exhibited dose‑ and time‑dependent antitumour activity. Furthermore, VEGI174, V7 and V8 inhibited tumour growth in A498 and 786‑O xenograft mice. In the A498 xenografts, the tumour growth inhibition (TGI) rates in the VEGI174‑, V7‑ and V8‑treated groups were 71, 20 and 31%, respectively. In the 786‑O xenografts, the TGI rates in the VEGI174‑, V7‑ and V8‑treated groups were 34, 26 and 31%, respectively. There was no significant loss in body weight and no cases of mortality were observed for all treated mice. In conclusion, VEGI174, V7 and V8 exhibited potential antitumour effects and were well tolerated in vivo. V7 and V8, as functional domain peptides of the VEGI174 protein, may be studied for the future treatment of RCC.
Insights
Vascular endothelial growth inhibitor (VEGI) protein and its peptides V7 and V8 show potential in treating renal cell carcinoma (RCC). These agents effectively inhibited cancer cell growth and tumor development in preclinical models with good tolerability.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Vascular endothelial growth inhibitor (VEGI) is an anti-angiogenic cytokine.
- The therapeutic potential of VEGI174 protein and its functional domain peptides (V7, V8) in renal cell carcinoma (RCC) is unexplored.
Purpose of the Study:
- To investigate the anti-cancer effects of biosynthesized VEGI174 protein, V7, and V8 peptides on RCC cell lines and a mouse xenograft model.
- To evaluate the impact of these agents on cancer cell proliferation, migration, and invasion, as well as tumor growth in vivo.
Main Methods:
- Treatment of A498 and 786-O RCC cell lines and a mouse xenograft model with VEGI174, V7, or V8.
- Assessment of cellular functions (proliferation, migration, invasion) using the xCELLigence system.
- Monitoring of tumor growth and mouse behavior (mobility, appetite, body weight) in xenograft models.
Main Results:
- VEGI174, V7, and V8 significantly inhibited proliferation, migration, and invasion of RCC cell lines in a dose- and time-dependent manner.
- All tested agents demonstrated significant tumor growth inhibition (TGI) in both A498 and 786-O xenograft models, with VEGI174 showing the highest TGI in A498.
- No significant adverse effects on mouse body weight or mortality were observed, indicating good in vivo tolerability.
Conclusions:
- VEGI174 protein and its functional peptides V7 and V8 possess significant anti-tumor properties against renal cell carcinoma.
- These agents were well-tolerated in preclinical studies, suggesting their potential as novel therapeutic candidates for RCC treatment.
- V7 and V8 peptides, derived from VEGI174, warrant further investigation for future clinical application in RCC therapy.
More Related Videos
15:43Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Mechanical Protein Functions
Conservation of Protein Domains
Structural Protein Function
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity. In bones and teeth, it mineralizes to...
Structural Protein Function
RNA Polymerase II Accessory Proteins